125 related articles for article (PubMed ID: 38409757)
1. Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177 Lu-Prostate-Specific Membrane Antigen Scan.
Taghavi M; Ahmadi R; Qutbi M
Clin Nucl Med; 2024 May; 49(5):e217-e218. PubMed ID: 38409757
[TBL] [Abstract][Full Text] [Related]
2. Combining enzalutamide and [
Houédé N; Hebert K
Lancet Oncol; 2024 May; 25(5):531-533. PubMed ID: 38621399
[No Abstract] [Full Text] [Related]
3. Dual 177 Lu-Prostate-Specific Membrane Antigen and 177 Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation.
Beyhan E; Erol Fenercioğlu Ö; Şahin R; Çermik TF; Ergül N
Clin Nucl Med; 2024 May; 49(5):447-448. PubMed ID: 38409763
[TBL] [Abstract][Full Text] [Related]
4. Sequential and Combination Therapies of
Jadvar H
J Nucl Med; 2023 Dec; 64(12):1932-1933. PubMed ID: 37827840
[No Abstract] [Full Text] [Related]
5. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
6. Whole-Body 177Lu-Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient.
Askari E; Moghadam SZ; Divband G; Aryana K
Clin Nucl Med; 2020 Oct; 45(10):805-807. PubMed ID: 32604118
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review.
Nautiyal A; Jha AK; Mithun S; Rangarajan V
Nucl Med Commun; 2022 Apr; 43(4):369-377. PubMed ID: 35045551
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
Ghodsirad MA; Pirayesh E; Akbarian R; Javanmard B; Kaghazchi F; Tavakoli M; Fattahi K
Urol J; 2020 Jun; 17(4):374-378. PubMed ID: 32281092
[TBL] [Abstract][Full Text] [Related]
11. Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression.
Pirayesh E; Tavakoli M
Mol Imaging Radionucl Ther; 2023 Feb; 32(1):54-56. PubMed ID: 36819190
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
Has Simsek D; Civan C; Ekenel M; Kuyumcu S; Sanli Y
Clin Nucl Med; 2021 May; 46(5):415-418. PubMed ID: 33630811
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen.
Rathore R; Rangrej SB; Kieme I; Carvalho V; King K; Amadou Y; McKinley J; Masawi A
Cureus; 2023 Apr; 15(4):e37778. PubMed ID: 37214073
[TBL] [Abstract][Full Text] [Related]
14. Radioligand Therapy With 177Lu-Prostate-Specific Membrane Antigen in a Patient With Non-Prostate-Specific Antigen-Secreting Metastatic Prostate Cancer.
Pirayesh E
Clin Nucl Med; 2020 Oct; 45(10):789-791. PubMed ID: 32701808
[TBL] [Abstract][Full Text] [Related]
15. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
16. Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer.
Yu XY; Zhu YQ; Liu X; Tian R; Chen JJ; Liu GQ; Yang DY; Zhang XP; Li B; Zhao HJ; Li X
Front Oncol; 2023; 13():1289272. PubMed ID: 38152366
[TBL] [Abstract][Full Text] [Related]
17. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
Aryana K; Zarehparvar Moghadam S; Salek R; Divband G
Clin Nucl Med; 2018 Apr; 43(4):273-275. PubMed ID: 29401146
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor.
Prabhu M; Damle NA; Gupta R; Arora S; Arunraj ST; Bal C
Indian J Nucl Med; 2018; 33(3):257-258. PubMed ID: 29962731
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-PSMA PET/CT Images of Multiple Cutaneous Metastases in a Patient With Prostate Carcinoma: Complete Response to 177Lu-PSMA-617 Treatment.
Sivrikoz IA; Deveci H; Ak AM; Acer E
Clin Nucl Med; 2023 Nov; 48(11):950-952. PubMed ID: 37812519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
